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Abstract 
Purpose: To assess drug utilization and expenditure trends in Medicaid fee-for-service program during 
the period 2010 – 2012 in the United States of America. 
Methods: A retrospective, descriptive analysis of the trend in drug utilization and expenditures in the 
Medicaid fee-for-service (FFS) program was performed using Medicaid state drug utilization data 
provided by Centers for Medicare and Medicaid Services (CMS) in the United States. Descriptive 
analyses were performed for all variables in the study. Association between prescription-drug utilization 
and reimbursement rate was examined using a linear regression model. 
Results: The results indicate that prescription-drug utilization of Medicaid FFS program decreased by 
20 % during the period (2010 – 2012) as also drug expenditure during the same period. Although 
constituting nearly 70 % and about 75 % of the total drug utilization in 2010 and 2012, respectively, 
generics represent only around 18 % of the total drug expenditures. No statistically significant 
association was found between total expenditures and the reimbursement rate. 
Conclusion: FFS Medicaid drug expenditures decreased from 2010 to 2012 mainly due to a reduction 
in the total number of prescriptions as also the prices of generic drugs. Thus, higher utilization of 
generic drugs may offer substantial savings to Medicaid programs at the state level. 
 
Keywords: Fee-for-service programs, Medicaid program, Generic drug utilization; Branded drugs, 
Patient Protection and Affordable Care Act 
 
This is an Open Access article that uses a funding model which does not charge readers or their institutions 
for access and distributed under the terms of the Creative Commons Attribution License 
(http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative 
(http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and 
reproduction in any medium, provided the original work is properly credited. 
Tropical Journal  of Pharmaceutical Research is indexed by Science Citation Index (SciSearch), Scopus, 
International Pharmaceutical Abstract, Chemical Abstracts, Embase, Index Copernicus, EBSCO, African 
Index Medicus, JournalSeek, Journal Citation Reports/Science Edition, Directory of Open Access Journals 




Medicaid is the largest healthcare insurance in 
the nation, and it is the key source of prescription 
medications for low-income Americans. 
According to a recent report by Kaiser, over 60 
million Americans were covered under Medicaid 
[1]. Patient Protection and Affordable Care Act 
(ACA) expanded the eligibility of the Medicaid 
program to millions of Americans [2,3]. Under the 
new healthcare reform, the prescription drugs 
paid by Medicaid will be significantly increase. 
-----------------------------------------------------------------------------------------------------------------------------------------------------
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Rising prescriptions drug costs are a challenge 
for Medicaid programs, and cost-containment 
strategies are needed [4]. 
 
Medicaid programs have implemented a variety 
of policies aiming to control drug costs [5]. State 
Medicaid programs use different criteria to set 
the reimbursement for branded and generic 
drugs to control their spending on prescription 
medication [5,6]. The simplest strategy used is 
an increase in generic drug utilization. After the 
patent of a branded drug expires, a generic 
version of the drug will be available at a much 
lower cost [7]. Prices of generic drugs will 
continue to decline as more firms enter the 
generics market, which is known as a multidrug 
source [8]. Taking advantage of the prices of 
generic drugs can have a potential impact on 
expenses [9]. Using a low-cost, generic 
alternative of a branded drug when available 
provides substantial savings on medication 
expenditure in state Medicaid program [9,10]. 
 
Medicaid programs reimburse pharmacies for 
drugs prescribed to eligible beneficiaries [11]. 
Reimbursement, generic substitution, and 
dispensing fee vary among the states, and each 
state sets its own policies to control drug 
spending [12]. Utilizing more generic drugs and 
setting appropriate pharmacy reimbursement 
rates could result in substantial savings to the 
Medicaid program [13]. 
 
The differences among the states in criteria for 
reimbursement and dispensing fee amount 
highlights the need for a better understanding of 
the factors that affect drug utilization and 
expenditures. This study assesses drug 
utilization, expenditures, and reimbursement rate 





A retrospective, descriptive analysis was 
performed on state-level Medicaid data provided 
by the Centers for Medicare and Medicaid 
Services (CMS) to examine the trend in drug 
utilization and expenditure under the program 
[14]. Pharmacy reimbursement rate includes both 
ingredient cost and dispensing fees. Each state’s 
annual report includes information about the total 
number of claims, number of generics and 
branded drug claims, utilization percentage of 
both types of drugs, and total amount paid by 
each state for the two types. In addition, we 
estimated the average expenditure of generic 
and branded drugs as well as their average 
prices paid by Medicaid [15]. 
 
Fee-for-service Medicaid prescription utilization 
from 2010 to 2012 for 42 states was included in 
this study. Eight states were excluded because 
they did not report annual drug utilization report 




All variables in the study were descriptively 
analyzed. Continuous variables were calculated 
as confidence intervals (95 %). The association 
between ingredient cost, dispensing fees, and 
drug utilization was examined using a linear 
regression model. The US consumer price index 
(CPI) was used to adjust price levels to 2012 to 
account for inflation [15]. The significance level 
for variables in this study was set at p <0.05. All 
statistical analyses were performed using SPSS 




From 2010 to 2012, FFS Medicaid expenditures 
in the states studied fell from $23.0 billion to 
$18.7 billion, that is, a 14.9 % decrease. 
Medicaid fee-for-service spent about $21.4 billion 
out of $23 billion on drug ingredient cost in 2010, 
which was nearly 93 % of all Medicaid pharmacy 
spending with the remaining 7 % being spent on 
dispensing fee. The spending on ingredient cost 
and dispensing fee stood at 94 % and 6 %, 
respectively of all Medicaid pharmacy spending 
in 2012. 
 
Our analysis demonstrated that the total 
prescription-drug utilization in Medicaid program 
decreased by nearly 20 % from 351.2 million in 
2010 to 281.4 million claims in 2012. 
Approximately 70.6 % of all Medicaid 
prescriptions in 2010 were dispensed using 
generic drugs, and this figure reached 75.4 % by 
2012 (Table 1).  
 




2010 2011 2012 
Claims 
(million) 
351.2 333.3 253.7 
 Generics (%)  71 72 75 
 Branded (%) 29 28 25 
Expenditure ($ 
billion) 
23.5 25.0 18.6 
 Generics (%) 18 17 17 
 Branded (%) 82 83 83 
 
Generic drug utilization in Medicaid programs 
varied from 64 % (Connecticut) to 84 % (Hawaii) 
in 2010, and the corresponding rates were 67 % 
and 88 %, respectively in 2012, with eight states 
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(Kansas, Kentucky, Nebraska, Virginia, Georgia, 
Massachusetts, Hawaii, and Rhode Island) 
reporting more than 80 %. On the other hand, 
three states (Connecticut, Texas, and Florida) 
reported generics utilization at less than 70 % of 




Figure 1: Medicaid fee-for-service drug utilization by 
state (2012) 
 
States with higher generic drug utilization than 
the national average saved a significant amount 
on drug expenditure as the share of generic 
drugs varied from 15 % to 27 %. Expenditure on 
generic drugs accounted for only 17.9 % and 
18.0 % of total Medicaid drug expenditure in 
2010 and 2012, respectively (Figure 2). The 
average generic drugs reimbursement in 2010 
was $17.89 (95% CI, $16.63 - $19.14) which 
decreased in 2012 to $16.91 (95% CI, $14.48 - 
$19.34), which is nearly 12 times lower than the 
$197.34 (95% CI, $184.74 - $209.94) paid on 
average for branded drugs prescription. In 2012, 
the average reimbursement of branded drugs 
prescription increased to $235.93 (95% CI, 




Figure 2: Medicaid fee-for-service percentage of 
generic drugs utilization and expenditures (2010 - 
2012) 
 
State dispensing fees for branded drug ranged 
from $1.75 and $1.80 in New Hampshire and 
Ohio to a high of $11.51 - $15.11 in Idaho 
depending on total annual prescription volume. 
Idaho and Oregon were among the states that 
used the Average Acquisition Cost (AAC) 
method for reimbursement, and their dispensing 
fee were the highest across the state. The 
national average pharmacy dispensing fee for 
generic drugs was $4.34 ± $1.24 in 2010 and 
increased in 2012 to $4.60 ± $2.56 while the 
average dispensing fee for brand drugs 
increased from $4.10 ± $1.19 to $4.38 ± $2.58 
during the same period. 
 
We found no statistically significant association 
between total number of claims/expenditures and 





Figure 3: Medicaid fee-for-service average 




Medicaid program spent nearly $23 billion dollar 
on fee-for-service (FFS) prescription drugs for 
more than 351 million prescriptions. The number 
of prescription drugs paid by Medicaid declined 
to 253 million prescriptions in 2012 with a total 
cost of $18 billion dollars. From 2010 to 2012, 
generic utilization reached 75 % of all 
prescriptions paid by Medicaid. Utilization of 
generic drugs varies across states due to 
differences in states policies for reimbursement 
of prescription drugs, a possible variation in 
prescribing patterns, and differences in disease 
prevalence [16]. States promote dispensing of 
generic drugs as an approach to contain the high 
drug cost in their programs. Medicaid saving 
from generic drugs could be greater as the 
patents of top branded drugs expire. Once a low-
cost generic drug becomes available, it is critical 
that Medicaid does not reimburse a branded drug 
[17]. 
 
According to our analysis, the average price of a 
branded drug at $197.3 was about nine times 
higher than that of generic drugs, which stood at 
$17.89 in 2010. The average price Medicaid paid 
for branded drugs increased to $235.9, about 14 
times higher than that paid for the generic 
alternatives in 2012. Medicaid saved an average 
$220 when the pharmacies dispensed a low-cost 
generic drug instead of a branded one. Although 
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branded drugs represented only 25 % of the total 
prescription, it accounted for more than 83 % of 
the total cost of prescription drugs under 
Medicaid. The remaining 75 % prescriptions 
were dispensed using a low-cost generic drug, 
and this constituted only 17 % of Medicaid 
prescription drug spending. This indicates that 
Medicaid could achieve substantial savings by 
encouraging the use of generic drugs. 
 
The number of prescription drugs are expected 
to increase in 2014 due to the new healthcare 
reform in which millions of uninsured or 
inadequately insured Americans will be covered 
under the Medicaid program [18]. This upcoming 
expansion will have a significant impact on 
Medicaid’s expenditure on prescription drugs and 
utilization [19]. This demonstrates that managing 
the growth in prescription spending is important 
for each Medicaid program. States have 
developed numerous strategies to contain the 
high drug costs. They have set a different 
reimbursement rate and dispensing fee for 
branded and generic drug [20,21]. They also 
seek to promote use of the generic version of 
drugs if available by incentivizing to pharmacies 
to dispense such a version [13,22]. Other 
strategies include requiring prior authorization for 
branded drugs, setting higher copayment for 
branded drugs, and mandating generic 
substitution and a preferred drugs list [4]. 
 
Our analysis demonstrates a substantial 
difference in drug utilization rates, ingredient 
costs, dispensing fees, and reimbursement rate 
in the Medicaid programs. These differences 
indicate the opportunities available for 
encouraging the prescription payment in the 
state Medicaid fee-for-service system [23]. 
Medicaid policies for drug reimbursement have a 
significant impact on promoting the dispensing of 
generic drugs [24]. Increased reimbursement for 
generic drugs could incentivize pharmacies to 
dispense such drugs and increase their utilization 
thus yielding additional savings on Medicaid FFS 
programs. 
 
Limitations of the study 
 
This study has some limitations. Characteristics 
and clinical information of the Medicaid 
population were not available in Medicaid 
pharmacy claims data that we used in this study. 
Accordingly, we were unable to assess the 
impact of utilization and expenditure on Medicaid 
beneficiaries’ outcomes. Higher expenditures 
could be associated with better treatment 
outcomes. Another limitation is that the total drug 
expenditure could be overestimated as data 
provided by CMS did not include information 
about drug manufacturer rebates, which could 
affect the total drug cost paid by Medicaid 
program. Finally, utilization and expenditures of 
Medicaid FFS program presented in this study 





This study found variations in generic utilization 
across states between 2010 and 2012. 
Reduction in the total volume of prescription 
drugs as well as prices of generic drugs in the 
period 2010 - 2012 contributed to lower 
pharmacy expenditures. On average, 75 % of all 
prescriptions paid by Medicaid are generics. 
Nearly 50 % of the states show generics 
utilization in Medicaid at lower than the national 
average of 75 %. These findings suggest that 
additional savings can be achieved by 
encouraging and promoting generic drugs use in 
Medicaid programs, especially in states with 
lower generics utilization rate.  
 
To improve the level of generic drugs utilization, 
Medicaid programs should adequately reimburse 
pharmacies to encourage them to dispense such 
drugs. Variation in reimbursement rate 
(dispensing fees and ingredient costs) across 
different FFS Medicaid programs are 
independent of total volume of prescription. 
Future studies that identify and evaluate the 
dispensing pattern of branded drugs when a low-
cost generic is available might disclose the 
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